NeoGenomics (NEO) Tops Q3 EPS by 4c, provides guidance

NeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.05, $0.04 better than the analyst estimate of $0.01. Revenue for the quarter came in at $167.82 million versus the consensus estimate of $166.98 million.

GUIDANCE:

NeoGenomics sees FY2024 revenue of $655-667 million, versus the consensus of $661.9 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• EQT And KKKR Said Among Firms Considering Bids For Qiagen - Bloomberg
• D. Boral Capital Acted as Sole Bookrunner to NorthStrive Acquisition Corp I. (Nasdaq:NSAIU) in Connection with its $100,000,000 Initial Public Offering
• Trump Sets Jan. 1, 2027 For 50% Canada Tariff Hike